Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442943 | 0.86 | ROCK2 (0.58) | ROCK2 | |
| SCHEMBL21490339 | 0.86 | ROCK2 (0.58) | ROCK2 | |
| SCHEMBL22396342 | 0.83 | ROCK2 (0.60) | ROCK2 | |
| SCHEMBL30356981 | 0.83 | ROCK2 (0.60) | ROCK2 | |
| SCHEMBL29442924 | 0.83 | ROCK2 (0.53) | ROCK2 | |
| SCHEMBL21490345 | 0.83 | ROCK2 (0.53) | ROCK2 | |
| SCHEMBL23529138 | 0.82 | ROCK2 (0.51) | ROCK2 | |
| SCHEMBL30167264 | 0.82 | ROCK2 (0.51) | ROCK2 | |
| SCHEMBL21490336 | 0.81 | ROCK2 (0.53) | ROCK2 | |
| SCHEMBL29442947 | 0.81 | ROCK2 (0.53) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704121-B1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3704121-B1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11192891-B2 | Diazaspiro ROCK inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192891-B2 | Diazaspiro ROCK inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3704121-A1 | DIAZASPIRO ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192891-B2 | Diazaspiro ROCK inhibitors | ROCK1, MYLK, ROCK2 | ROCK2 3/4885 |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | ROCK1, MYLK, ROCK2 | ROCK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.